- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- F-1/A Registration statement (foreign)
- 3.1 Form of Amended and Restated Articles of Association of NLS Pharmaceutics LTD.
- 10.20 Amendment Number 2 to Convertible Loan Agreement Dated February 21, 2020 Between NLS Pharmaceutics LTD. and Alexander Zwyer
- 10.21 Amendment Number 3 to Convertible Loan Agreement Dated February 21, 2020 Between NLS Pharmaceutics LTD. and Alexander Zwyer
- 10.22 Bridgeloan Agreement Between NLS Pharmaceutics LTD. and Magnetic Rock Investment Ag
- 10.23 Amendment to Bridge Loan Agreement Between NLS Pharmaceutics LTD. and Magnetic Rock Investment Ag
- 10.24 Form of Amendment to Convertible Loan Agreement Between NLS Pharmaceutics LTD. and Certain Lenders
- 10.25 Form of Addendum Number 3 to Promissory Note Dated January 2019 Between Certain Investors and the Company
- 10.26 Addendum Number 3 to Credit Facility Dated August 31, 2015 Between NLS Pharma Ag and the Lenders Named Therein
- 10.27 Addendum Number 3 to Credit Facility Dated August 31, 2015 Between NLS-1 Pharma Ag and the Lenders Named Therein
- 10.28 Addendum Number 2 to Convertible Promissory Note Dated January 18, 2019 Between Magnetic Rock Investment Ag and the Company
- 23.1 Consent of Marcum LLP
- 99.1 Consent of Stig Lokke Pedersen
- 99.2 Consent of Myoung-ok Kwon
- 4 Oct 21 EFFECT Notice of effectiveness
- 30 Sep 21 POS AM Prospectus update (post-effective amendment)
- 7 Jun 21 EFFECT Notice of effectiveness
- 27 May 21 POS AM Prospectus update (post-effective amendment)
- 2 Feb 21 POS EX Additional exhibits for listing
- 1 Feb 21 424B4 Prospectus supplement with pricing info
- 29 Jan 21 EFFECT Notice of effectiveness
- 20 Jan 21 F-1/A Registration statement (foreign) (amended)
- 17 Nov 20 F-1/A Registration statement (foreign) (amended)
- 13 Nov 20 F-1/A Registration statement (foreign) (amended)
-
16 Oct 20 F-1/A Registration statement (foreign) (amended)
- 31 Aug 20 F-1/A Registration statement (foreign) (amended)
- 28 Feb 20 F-1 Registration statement (foreign)
Exhibit 23.1
Independent Registered Public Accounting Firm’s Consent
We consent to the inclusion in this Registration Statement of NLS Pharmaceutics Ltd. on Form F-1 Amendment No. 2 (File No. 333-236797) of our report dated August 31, 2020, except for Note 1A as to which the date is October 16, 2020, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, with respect to our audits of the financial statements of NLS Pharmaceutics Ltd. as of December 31, 2019 and 2018 and for each of the two years in the period ended December 31, 2019, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
/s/ Marcum llp
Marcum llp
New York, NY
October 16, 2020